Biomarin Pharmaceutical (BMRN) risk factors
Item 1A of every Biomarin Pharmaceutical Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors50 risks12 new7 dropped16 reworded
BioMarin's risk profile now centers heavily on its aggressive M&A strategy, specifically the proposed acquisition of Amicus and completed purchase of Inozyme. The company is taking on substantial integration challenges, increased debt obligations including $850.0 million in 2034 notes, and new U.S. regulatory and tax pressures.
Filed Feb 26, 2026 - FY2024 10-K risk factors45 risks
BioMarin's risk profile centers on managing $1.7 billion in cash and $600 million in 2027 Notes while executing a new 2024 corporate growth strategy. Key threats include reliance on small patient populations for products like BRINEURA and VIMIZIM, single-source manufacturing vulnerabilities, and international pricing pressures.
Filed Feb 24, 2025